Summary by Moomoo AI
Clearmind Medicine Inc., a biotechnology company, has filed an amended annual report for the fiscal year ended October 31, 2023. The amendment, submitted to the United States Securities and Exchange Commission, includes certifications by the company's principal executive officer and principal financial officer, which were previously omitted. The company's common shares are listed on The Nasdaq Stock Market under the symbol CMND, with 607,337 common shares outstanding as of the report's fiscal year-end. Clearmind Medicine is classified as an emerging growth company and a non-accelerated filer according to the SEC's definitions. The company has complied with all reporting requirements of the Exchange Act for the past 12 months and has submitted all required Interactive Data Files. The financial...Show More